CarsonAllaria Wealth Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

CarsonAllaria Wealth Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-8	Closed	-$849	–	211
2025 Q2	$849	Hold	8	–	–	﹤0.01%	341
2025 Q1	$993	Hold	8	–	–	﹤0.01%	346
2024 Q4	$985	Hold	8	–	–	﹤0.01%	329
2024 Q3	$891	Hold	8	–	–	﹤0.01%	367
2024 Q2	$854	Hold	8	–	–	﹤0.01%	354
2024 Q1	$963	Hold	8	–	–	﹤0.01%	367
2023 Q4	$984	Hold	8	–	–	﹤0.01%	330
2023 Q3	$1.04K	Hold	8	–	–	﹤0.01%	333
2023 Q2	$992	Hold	8	–	–	﹤0.01%	353
2023 Q1	$1.17K	Hold	8	–	–	﹤0.01%	327
2022 Q4	$1K	Hold	8	–	–	﹤0.01%	319
2022 Q3	$1K	Hold	8	–	–	﹤0.01%	315
2022 Q2	$1K	Hold	8	–	–	﹤0.01%	310
2022 Q1	$1K	Hold	8	–	–	﹤0.01%	320
2021 Q4	$1K	Buy	+8	New	+$1.05K	﹤0.01%	344

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

CarsonAllaria Wealth Management's JAZZ Position: Q3 2025 in Review

CarsonAllaria Wealth Management sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2025, closing a stake of 8 shares — an estimated $849 sold.

CarsonAllaria Wealth Management first reported a position in JAZZ in Q4 2021 and held it in 15 quarters. The position peaked at $1.17K in Q1 2023. 503 funds tracked by Wall St. Rank hold JAZZ as of Q3 2025.

CarsonAllaria Wealth Management reported no remaining Jazz Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
CarsonAllaria Wealth Management sold 8 Jazz Pharmaceuticals shares in Q3 2025, an estimated $849.
CarsonAllaria Wealth Management first reported a position in Jazz Pharmaceuticals in Q4 2021 and held it in 15 quarters.
CarsonAllaria Wealth Management's Jazz Pharmaceuticals position peaked at $1.17K in Q1 2023.
503 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2025.

Based on CarsonAllaria Wealth Management's 13F filing for Q3 2025, filed 28 Oct 2025.